241 related articles for article (PubMed ID: 11363842)
1. Outdated yet out-of-reach: AIDS society treatment guidelines at the International Conference.
Torres G
GMHC Treat Issues; 1996 Sep; 10(9):7, 10-1. PubMed ID: 11363842
[TBL] [Abstract][Full Text] [Related]
2. Top AIDS researchers' strategy for antiretroviral treatment.
AIDS Alert; 1996 Sep; 11(9):97-100. PubMed ID: 11363728
[TBL] [Abstract][Full Text] [Related]
3. ACTG 175 and Delta.
Torres G
GMHC Treat Issues; 1995 Oct; 9(10):2-3. PubMed ID: 11362915
[TBL] [Abstract][Full Text] [Related]
4. ACTG 175: new insights into treating patients with intermediate-stage HIV disease.
Folkers G
NIAID AIDS Agenda; 1995 Dec; ():4-5. PubMed ID: 11363352
[TBL] [Abstract][Full Text] [Related]
5. AZT studies reinforce benefits of combination.
AIDS Alert; 1995 Jan; 10(1):11-2. PubMed ID: 11362167
[TBL] [Abstract][Full Text] [Related]
6. Studies confirm value of early and combination treatments.
Vazquez E
Posit Aware; 1995; VI(6):8. PubMed ID: 11363148
[TBL] [Abstract][Full Text] [Related]
7. Study results at a glance.
AIDS Alert; 1995 Nov; 10(11):134. PubMed ID: 11362922
[TBL] [Abstract][Full Text] [Related]
8. New double vs. triple antiviral combination study, CD4 200-500, no prior treatment.
James JS
AIDS Treat News; 1995 Dec; (no 236):7. PubMed ID: 11363052
[TBL] [Abstract][Full Text] [Related]
9. New trials reach same conclusion: two drugs are better than AZT alone.
AIDS Alert; 1995 Nov; 10(11):133-6. PubMed ID: 11362921
[TBL] [Abstract][Full Text] [Related]
10. Benefits of combination therapy confirmed.
Cheng B
PI Perspect; 1995 Dec; (no 17):3-4. PubMed ID: 11363111
[TBL] [Abstract][Full Text] [Related]
11. Major protease inhibitor triple combination trial begins soon: CD4 under 200, AZT experienced, 3TC naive.
James JS
AIDS Treat News; 1995 Dec; (no 237):3. PubMed ID: 11363075
[TBL] [Abstract][Full Text] [Related]
12. 3TC approval may revive AZT's appeal.
Vazquez E
Posit Aware; 1996; 7(1):8-9. PubMed ID: 11363136
[TBL] [Abstract][Full Text] [Related]
13. Antiretroviral combination treatment prolongs life in people with HIV/AIDS.
Cooper EC
AMFAR Rep; 1996 Jan; ():1-5. PubMed ID: 11363617
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy increases survival.
Treat Rev; 1995 Nov; (no 20):2-3. PubMed ID: 11363019
[TBL] [Abstract][Full Text] [Related]
15. To treat or not to treat--approaches to antiretroviral therapy. Interview by Anthony J. Japour.
Coombs R; Cotton D; Hammer S; Saag M; van der Horst C
AIDS Clin Care; 1996 Jan; 8(1):1-4. PubMed ID: 11363056
[TBL] [Abstract][Full Text] [Related]
16. Major study shows AZT monotherapy inferior.
James JS
AIDS Treat News; 1995 Sep; (no 231):3-4. PubMed ID: 11362867
[TBL] [Abstract][Full Text] [Related]
17. AIDS therapy with two, three or four agent combinations, applied in short sequences, differing from each other by drug rotation. I. First of two parts: a phase I trial equivalent, concerning five virostatics: AZT, ddI, ddC, acriflavine and an ellipticine analogue.
Mathé G; Pontiggia P; Orbach-Arbouys S; Triana K; Ambetima N; Morette C; Hallard M; Blanquet D
Biomed Pharmacother; 1996; 50(5):220-7. PubMed ID: 8949403
[TBL] [Abstract][Full Text] [Related]
18. FDA triple header. Food and Drug Administration.
Smart T
GMHC Treat Issues; 1995 Nov; 9(11):1-3. PubMed ID: 11362986
[TBL] [Abstract][Full Text] [Related]
19. Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults.
Darbyshire J; Foulkes M; Peto R; Duncan W; Babiker A; Collins R; Hughes M; Peto T; Walker A
Cochrane Database Syst Rev; 2000; (3):CD002038. PubMed ID: 10908523
[TBL] [Abstract][Full Text] [Related]
20. Potent new AIDS drugs underscore promise of combination therapy.
AIDS Alert; 1996 Jan; 11(1):1-4. PubMed ID: 11363225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
